These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7395889)

  • 1. Hemodialysis of mefenamic acid in uremic patients.
    Wang LH; Lee CS; Marbury TC
    Am J Hosp Pharm; 1980 Jul; 37(7):956-8. PubMed ID: 7395889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
    Marbury TC; Lee CS; Perchalski RJ; Wilder BJ
    Am J Hosp Pharm; 1981 Nov; 38(11):1757-60. PubMed ID: 7304633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of dyphylline elimination by uremic patients.
    Lee CC; Wang LH; Majeske BL; Marbury TC
    J Pharmacol Exp Ther; 1981 May; 217(2):340-4. PubMed ID: 7229976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis.
    Lee CS; Wang LH; Marbury TC; Bruni J; Perchalski RJ
    Clin Toxicol; 1980 Oct; 17(3):429-38. PubMed ID: 7449356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
    Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
    Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis.
    Shahbazian H; Zand Moghadam A; Ehsanpour A; Khazaali M
    Iran J Kidney Dis; 2009 Jul; 3(3):151-5. PubMed ID: 19617664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. II. On hemodialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):255-9. PubMed ID: 881277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hemodialysis on total body clearance of chloramphenicol.
    Slaughter RL; Cerra FB; Koup JR
    Am J Hosp Pharm; 1980 Aug; 37(8):1083-6. PubMed ID: 7405936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption and disposition of ibuprofen in hemodialyzed uremic patients.
    Senekjian HO; Lee CS; Kuo TH; Au DS; Krothapalli R
    Eur J Rheumatol Inflamm; 1983; 6(2):155-62. PubMed ID: 6673979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of ceftriaxone in hemodialysis].
    Laville M; Mercatello A; Freney J; Pozet N; Meugnier H; Labeeuw M; Fleurette J; Zech P
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):719-23. PubMed ID: 3309803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
    Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
    Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
    Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
    Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodialysis clearance of total and unbound lidocaine.
    Jacobi J; McGory RW; McCoy H; Matzke GR
    Clin Pharm; 1983; 2(1):54-7. PubMed ID: 6883930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F; Floridi AG; Floridi A; Buoncristiani U
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Citrate kinetics in patients receiving long-term hemodialysis therapy.
    Bauer E; Derfler K; Joukhadar C; Druml W
    Am J Kidney Dis; 2005 Nov; 46(5):903-7. PubMed ID: 16253731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.